BIOHIT
Innovating for Health

DATA SHEET

PRODUCT NAME AND CLONE: The original BIOHIT Monoclonal antibody against **PEPSINOGEN II,** Clone L10CC10.

HOST: Mouse

IMMUNOGEN: Monoclonal antibody to pepsinogen II is derived from the hybridoma produced by fusion between myeloma cells and Balb/c spleen cells. Pepsinogen II purified from human tissue was used as an immunogen.

CLASS AND SUBCLASS: IgG_1

PRODUCT SPECIFITY: The antibody is specific to human pepsinogen II and has no cross reactivity to human pepsinogen I.

PRODUCT CODE:
610056: 100 µg/ml vial 100 µg
610060: 100 µg/ml vial 1 mg

PRODUCT BUFFER: PBS solution containing 1.0% (w/v) BSA and 0.09% (w/v) NaN_3.

Other MAb concentrations and buffer compositions are available upon request.

STORAGE: 2 to 8°C

APPLICATIONS: Immunohistochemical staining, western blotting and enzyme-immunoassays.

REFERENCES:

1. Varis K. Surveillance of pernicious anemia. In Precancerous Lesions of the Gastrointestinal Tract. Scherlock P, Morson PC, Barbara L, Veronesi U (eds), Raven Press, New York, 189-194, 1983.
2. Varis K, Samloff IM, Ihamäki T, Siurala M. An appraisal of tests for severe atrophic gastritis in relatives of patients with pernicious anemia. Dig. Dis. Sci., 24: 187–191, 1979.
3. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int. J. Cancer, 35: 173–177, 1985.
4. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurent of serum pepsinogens. Jpn. J. Cancer Res., 86: 1210–1215, 1995.
5. Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Tanka S, Kajiyama G, Shigenobu T. The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography. Hiroshima J. Med. Sci., 46: 81–86, 1997.
6. Aoki K, Misumi J, Kimura T, Zhao W, Xie T. Evaluation of cut-off levels for screening of gastric cancer using serum pepsinogens and distribution of levels of serum pepsinogen I, II and of PG1/PGII ratios in a gastric cancer case-control study. J. Epidemiol., 7: 143–151, 1997.
7. Kikuchi S, Wada O, Miki K, Nakajima T, Nishi T, Kobayashi O, Inaba Y. Serum pepsinogen as a new marker for gastric carsinoma among young adults. Research group on prevention of gastric carsinoma among young adults. Cancer, 73: 2695–2702, 1994.
8. Farinati F, Di Mario F, Plebani M, Cielo R, Fanton MC, Valiante F, Masiero M, DeBoni M, Della Libera G, Burlin A. Pepsinogen A/Pepsinogen C or Pepsinogen A multiplied by gastrin in the diagnosis of gastric cancer. Ital. J. Gastroenterol., 23: 194–206, 1991.
9. Borch K, Axelsson CK, Halgreen H, Damkjaer Nielsen MD, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand. J. Gastroenterol., 24: 870–876, 1989.
10. Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Kitadai Y, Komoto K, Tanka S, Kajiyama G. Correlation of ratio of serum papsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am. J. Gastroenterol., 93: 1090–1096, 1998.

The product is for research use and further manufacturing only. Use in human clinical diagnostics is the responsibility of the user.

DS56 ver 7